NYSE:NVTA Invitae (NVTA) Stock Forecast, Price & News $0.61 -0.02 (-3.19%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$0.60▼$0.6550-Day Range$0.61▼$1.4552-Week Range$0.60▼$3.78Volume9.30 million shsAverage Volume8.89 million shsMarket Capitalization$162.18 millionP/E RatioN/ADividend YieldN/APrice Target$2.08 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Invitae MarketRank™ ForecastAnalyst RatingStrong Sell1.40 Rating ScoreUpside/Downside241.6% Upside$2.08 Price TargetShort InterestBearish16.78% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews Sentiment0.22Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.41) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector781st out of 969 stocksMedical Laboratories Industry20th out of 25 stocks 2.7 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Strong Sell. The company's average rating score is 1.40, and is based on no buy ratings, 2 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.08, Invitae has a forecasted upside of 241.6% from its current price of $0.61.Amount of Analyst CoverageInvitae has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.78% of the outstanding shares of Invitae have been sold short.Short Interest Ratio / Days to CoverInvitae has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Invitae has recently increased by 13.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 70.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.14. Previous Next 1.8 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Invitae this week, compared to 2 articles on an average week.Search Interest32 people have searched for NVTA on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of Invitae is held by insiders.Percentage Held by Institutions61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.41) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Invitae (NYSE:NVTA) StockInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More NVTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTA Stock News HeadlinesSeptember 23, 2023 | uk.news.yahoo.comInvitae aims to regain NYSE compliance after average share price falls below $1September 22, 2023 | finance.yahoo.comInvitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing StandardSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 21, 2023 | finance.yahoo.comInvitae Stock Analysis: Buy, Sell, or Hold?September 21, 2023 | americanbankingnews.comInvitae (NYSE:NVTA) Downgraded to Sell at StockNews.comSeptember 21, 2023 | americanbankingnews.comBrokerages Set Invitae Co. (NYSE:NVTA) PT at $2.08September 14, 2023 | finance.yahoo.comCathie Wood Is Betting on This Struggling Stock. Should You?September 4, 2023 | finance.yahoo.comGreat week for Invitae Corporation (NYSE:NVTA) institutional investors after losing 65% over the previous yearSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 28, 2023 | finance.yahoo.comInvitae Hires Industry Veteran Robert Guigley as Chief Commercial OfficerAugust 24, 2023 | finance.yahoo.comWhy Invitae Stock Is Crashing TodayAugust 15, 2023 | msn.comPiper Sandler Maintains Invitae (NVTA) Underweight RecommendationAugust 15, 2023 | markets.businessinsider.comInvitae Says Clinical Trial Results Support Genetic Testing Of Patients With Prostate CancerAugust 15, 2023 | markets.businessinsider.comPiper Sandler Maintains Underweight Rating for Invitae: Here's What You Need To KnowAugust 15, 2023 | finance.yahoo.comClinical Trial Results Support Genetic Testing of All Patients with Prostate CancerAugust 11, 2023 | finance.yahoo.comDown 96%, Is Invitae Stock a Buy?August 9, 2023 | finance.yahoo.comInvitae (NVTA) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | finance.yahoo.comInvitae Reports Second Quarter 2023 Financial ResultsJuly 28, 2023 | finance.yahoo.comBest Beaten-Down Growth Stock to Buy: Nano Dimension vs. InvitaeJuly 27, 2023 | msn.comDown 97%, Is It Finally Time to Buy Invitae Stock?July 27, 2023 | finance.yahoo.comInvitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023July 21, 2023 | finance.yahoo.comInvitae (NVTA) Upgraded to Buy: Here's WhyJuly 10, 2023 | nasdaq.comInvitae Corporation Common Stock (NVTA)June 8, 2023 | finance.yahoo.comInvitae Corporation (NYSE:NVTA) Stock's 27% Dive Might Signal An Opportunity But It Requires Some ScrutinyJune 5, 2023 | msn.comWall Street Says These 2 Stocks May Double. Should You Buy Them?May 31, 2023 | finance.yahoo.comInvitae to Present at the William Blair 43rd Annual Growth Stock ConferenceMay 26, 2023 | finance.yahoo.comNew Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in OncologySee More Headlines Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Company Calendar Last Earnings8/08/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.08 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+230.2%Consensus RatingStrong Sell Rating Score (0-4)1.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-161.92% Pretax Margin-163.60% Return on Equity-6,100.71% Return on Assets-19.72% Debt Debt-to-Equity Ratio15.68 Current Ratio2.97 Quick Ratio2.83 Sales & Book Value Annual Sales$516.30 million Price / Sales0.32 Cash Flow$7.86 per share Price / Cash Flow0.08 Book Value$0.42 per share Price / Book1.50Miscellaneous Outstanding Shares267,010,000Free Float265,038,000Market Cap$167.79 million OptionableOptionable Beta1.70 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Randal W. Scott Ph.D. (Age 65)Co-Founder & Chairman Comp: $50kMr. Kenneth D. Knight (Age 62)Pres, CEO & Director Comp: $1.4MMr. Thomas R. Brida (Age 52)Gen. Counsel, Chief Compliance Officer & Sec. Comp: $776.72kMr. Robert Dickey IV (Age 67)M.B.A., Interim Chief Financial Officer Mr. Jeffrey Parsons (Age 63)Interim Chief Accounting Officer Ms. Hoki Luk (Age 47)Head of Investor Relations and Capital Markets Ms. Shelly D. Guyer (Age 63)Chief Sustainability Officer Ms. Desarie FrenchChief Talent OfficerDr. W. Michael Korn M.D.Chief Medical OfficerMr. Jackson J. Finks C.F.A.CFA, Director of Investor Relations & Strategic Fin.More ExecutivesKey CompetitorsHH&L AcquisitionNYSE:HHLACelcuityNASDAQ:CELCBiodesixNASDAQ:BDSXMDxHealthNASDAQ:MDXHGenetronNASDAQ:GTHView All CompetitorsInsiders & InstitutionsBarclays PLCSold 104,017 shares on 9/21/2023Ownership: 0.042%California State Teachers Retirement SystemSold 205,951 shares on 8/21/2023Ownership: 0.033%IHT Wealth Management LLCBought 29,280 shares on 8/15/2023Ownership: 0.036%Royal Bank of CanadaBought 10,731 shares on 8/15/2023Ownership: 0.012%Gamco Investors INC. ET ALSold 22,500 shares on 8/15/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions NVTA Stock - Frequently Asked Questions Should I buy or sell Invitae stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" NVTA shares. View NVTA analyst ratings or view top-rated stocks. What is Invitae's stock price forecast for 2023? 5 equities research analysts have issued 12-month target prices for Invitae's stock. Their NVTA share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $2.08 in the next twelve months. This suggests a possible upside of 230.2% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts. How have NVTA shares performed in 2023? Invitae's stock was trading at $1.86 at the beginning of the year. Since then, NVTA stock has decreased by 66.2% and is now trading at $0.6284. View the best growth stocks for 2023 here. Are investors shorting Invitae? Invitae saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 39,310,000 shares, a drop of 32.9% from the August 15th total of 58,580,000 shares. Based on an average daily volume of 9,660,000 shares, the short-interest ratio is currently 4.1 days. View Invitae's Short Interest. When is Invitae's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our NVTA earnings forecast. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) issued its earnings results on Tuesday, August, 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. The medical research company earned $120.53 million during the quarter, compared to analysts' expectations of $121.19 million. Invitae had a negative net margin of 161.92% and a negative trailing twelve-month return on equity of 6,100.71%. What ETFs hold Invitae's stock? ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM) and ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK). What guidance has Invitae issued on next quarter's earnings? Invitae issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480.00 million-$500.00 million, compared to the consensus revenue estimate of $497.62 million. What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What is Invitae's stock symbol? Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." Who are Invitae's major shareholders? Invitae's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.38%), BlackRock Inc. (7.99%), Sumitomo Mitsui Trust Holdings Inc. (6.49%), State Street Corp (2.84%), Geode Capital Management LLC (1.80%) and Northern Trust Corp (0.82%). Insiders that own company stock include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen. View institutional ownership trends. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invitae's stock price today? One share of NVTA stock can currently be purchased for approximately $0.63. How much money does Invitae make? Invitae (NYSE:NVTA) has a market capitalization of $167.79 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. How many employees does Invitae have? The company employs 1,700 workers across the globe. How can I contact Invitae? Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com. This page (NYSE:NVTA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.